Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline Review, H2 2018’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

– The report reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics and enlists all their major and minor projects

– The report assesses Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CSL Ltd

GeNeuro SA

Immupharma Plc

Momenta Pharmaceuticals Inc

Octapharma AG

Pfizer Inc

Shire Plc

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Involved in Therapeutics Development

CSL Ltd

GeNeuro SA

Immupharma Plc

Momenta Pharmaceuticals Inc

Octapharma AG

Pfizer Inc

Shire Plc

Teijin Pharma Ltd

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug Profiles

forigerimod acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-2045 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNbAC-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hyaluronidase (recombinant, human) + immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Dormant Projects

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Discontinued Products

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Development Milestones

Featured News & Press Releases

Jun 15, 2018: CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology

Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data

Apr 20, 2018: CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting

Mar 16, 2018: FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Jan 26, 2018: CHMP Recommends Extension of Indications for Hizentra

Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Sep 14, 2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication

Jul 11, 2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders

Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed

Feb 14, 2017: FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition

Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy

Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen

Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by CSL Ltd, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by GeNeuro SA, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by Immupharma Plc, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by Momenta Pharmaceuticals Inc, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by Octapharma AG, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by Pfizer Inc, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by Shire Plc, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline by Teijin Pharma Ltd, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Dormant Projects, H2 2018

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports